GNX-102

N/A

Report date: 2025/02/19 11:50:50

First In Class

Base Information

Drug NameGNX-102

Drug Alias NameGNX-102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionLewis-Y antigen antagonistsLewis-B antigen inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects

TargetsLewis-Y antigenLewis-B antigen

Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlyconex Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesGlyconex Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

ATC CodeN/A